Obesity Medicine

FDA updates include oral GLP-1 therapy, HIV regimen, gene therapy for hearing loss, and diabetes technology advances.

Discussing how primary care clinicians can approach nutrition conversations with all patients in a non-judgmental, culturally responsive, and behaviorally informed way.

ACP Internal Medicine Meeting 2026 highlights: new mammography guidelines, AI scribe limitations, and muscle loss risks with GLP-1 weight loss drugs.

Explore monthly GLP‑1 dose titration, unusual strength jumps, and color‑coded pills—plus tips for switching safely from injectable regimens.

FDA approves orforglipron, a once-daily oral GLP‑1 for weight management, taken with food or coffee—simplifying obesity treatment.

The approval of Foundayo (orforglipron) marks a formulation milestone in obesity pharmacotherapy, offering a once-daily pill free of the fasting requirements that may complicate adherence.

From oral GLP-1s for obesity and T2D to a potential first new smoking cessation drug in 20 years, here are 5 FDA pipeline updates to put on your radar.

New FDA-approved semaglutide 7.2 mg shows ~21% weight loss, offering primary care clinicians a higher-efficacy obesity treatment option.

How primary care tackles obesity stigma with lifestyle, GLP-1-based medications, and team-based care.

The FDA issued 30 warning letters to telehealth firms for false or misleading claims about compounded GLP-1 products, citing illegal marketing practices.

In a phase 2 trial in China, UBT251 led to up to 19.7% mean weight loss at 24 weeks vs 2.0% with placebo in adults with overweight or obesity.

Swallowable gastric balloon, approved by the FDA, provides a non-invasive, surgery-free weight loss solution for patients with a BMI between 30 and 40.

In the REDEFINE 4 trial, CagriSema led to 23% weight loss at 84 weeks but did not demonstrate noninferiority to tirzepatide 15 mg in adults with obesity.

Data from a new meta-analysis shows weight loss therapies were associated with clinically and statistically significant improvements in psoriasis severity. Study investigators sheds light.

Adults with obesity achieved up to 12.1% mean weight loss with oral ribupatide vs placebo in a 26-week phase 2 trial.

Obesity medicine specialist Monu Khanna, MD, discusses the critical role of primary care in obesity-related risk reduction through lifestyle, behavior, and emerging therapies.

Roche's CT-388 shows promising results with 22.5% weight loss in a phase 2 trial, advancing obesity treatment options significantly.

FDA requests removal of suicidal ideation warnings from GLP-1 receptor agonist labeling after a comprehensive review found no increased risk.

The FDA approved once-daily oral semaglutide 25 mg for chronic weight management and long-term weight maintenance in adults with obesity or overweight, based on data from the OASIS clinical trial program.

Topline Phase 3 ATTAIN-MAINTAIN data show oral orforglipron met primary and key secondary endpoints for weight maintenance after prior GLP-1–based injectable therapy in adults with obesity.

The phase 3 REDFINE program showed mean weight loss of 20% at 68 weeks, supporting the dual-mechanism approach that combines semaglutide with cagrilintide.

Both doses of the GLP-1, GIP, glucagon triple agonist (9- and 12-mg) met all primary and key secondary endpoints and reduced CV risk factors as well, Eli Lilly said.

The 2026 annual updates to the Standards of Care in Diabetes include wider CGM use, guidance on dosing of antiobesity drugs, and glycemic management during cancer therapy.

Insulet enhances the Omnipod® 5 system with new glucose targets and algorithms, improving insulin delivery for diabetes management.

Biomarker trajectories over 5 years in study participants with AD show steeper rises in pTau217, NfL, and amyloid burden among those with obesity, highlighting risk factor relevance.